ES2093640T3 - Produccion de hemoglobina y sus analogos mediante bacterias y levadura. - Google Patents

Produccion de hemoglobina y sus analogos mediante bacterias y levadura.

Info

Publication number
ES2093640T3
ES2093640T3 ES90610036T ES90610036T ES2093640T3 ES 2093640 T3 ES2093640 T3 ES 2093640T3 ES 90610036 T ES90610036 T ES 90610036T ES 90610036 T ES90610036 T ES 90610036T ES 2093640 T3 ES2093640 T3 ES 2093640T3
Authority
ES
Spain
Prior art keywords
alpha
beta
hemoglobin
globin
expressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90610036T
Other languages
English (en)
Inventor
Stephen J Hoffman
Douglas L Looker
Mary S Rosendal
Gary L Stetler
Michael Wagenbach
Kiyoshi Nagai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Somatogen Inc
Original Assignee
Medical Research Council
Somatogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council, Somatogen Inc filed Critical Medical Research Council
Application granted granted Critical
Publication of ES2093640T3 publication Critical patent/ES2093640T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)

Abstract

SUBUNIDADES DE ALFA-HEMOGLOBINA QUE ACTUAN COMO UN NUEVO POLIPEPTIDO DE DI-ALFA-GLOBINA RECOMBINANTE QUE CONSTA DE LAS DOS SUBUNIDADES ALFA CONECTADAS DIRECTAMENTE MEDIANTE UN ENLACE DE PEPTIDO O INDIRECTAMENTE MEDIANTE UN AMINOACIDO FLEXIBLE O AGENTE DE UNION DE PEPTIDOS. LA DI-ALFA-GLOBINA PUEDE COMBINARSE "IN VIVO" O "IN VITRO" CON BETA-GLOBINA Y HEMO PARA FORMAR HEMOGLOBINA. LA HEMOGLOBINA HUMANA TETRAMERICA Y LA DI-ALFA/BETA2 HEMOGLOBINA SE PRODUCEN EN S. CEREVISIAE MEDIANTE TRES TIPOS DE VECTORES DE EXPRESION: 1) DOS PLASMIDOS SEPARADOS QUE CONTIENEN RESPECTIVAMENTE GENES DE ALFA- Y BETA-GLOBINA EXPRESADOS EN CEPAS DIPLOIDES, 2) UN PLASMIDO QUE CONSTA DE GENES DE ALFA- Y BETA-GLOBINA EXPRESADOS EN CEPAS HAPLOIDES O DIPLOIDES, 3) UN PLASMIDO QUE CONSTA DE GENES DE DI-ALFA- Y BETA-GLOBINA EXPRESADOS EN CEPAS HAPLOIDES. LA FORMA TETRAMERICA O LAS SUBUNIDADES SEPARADAS PUEDEN RECUPERARSE DE LA FRACCION SOLUBLE. POR LO TANTO, PUEDEN PRODUCIRSE 3 TIPOS DE MOLECULAS DEL TIPO HEMOGLOBINA:DI-ALFA/BETA, DI-BETA/DOS ALFA O DI-ALFA/DI-BETA, CON UNA VIDA LARGA O MEDIA.
ES90610036T 1989-05-10 1990-05-10 Produccion de hemoglobina y sus analogos mediante bacterias y levadura. Expired - Lifetime ES2093640T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34962389A 1989-05-10 1989-05-10
US37416189A 1989-06-30 1989-06-30
US37911689A 1989-07-13 1989-07-13

Publications (1)

Publication Number Publication Date
ES2093640T3 true ES2093640T3 (es) 1997-01-01

Family

ID=27407902

Family Applications (2)

Application Number Title Priority Date Filing Date
ES90610036T Expired - Lifetime ES2093640T3 (es) 1989-05-10 1990-05-10 Produccion de hemoglobina y sus analogos mediante bacterias y levadura.
ES95110064T Expired - Lifetime ES2204926T3 (es) 1989-05-10 1990-05-10 Procedimiento de preparacion de hemoglobina y derivados de hemoglobina a partir de manipulacion de bacterias y levaduras.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES95110064T Expired - Lifetime ES2204926T3 (es) 1989-05-10 1990-05-10 Procedimiento de preparacion de hemoglobina y derivados de hemoglobina a partir de manipulacion de bacterias y levaduras.

Country Status (18)

Country Link
EP (3) EP0700997B1 (es)
JP (1) JP3013902B2 (es)
KR (1) KR920701434A (es)
AT (2) ATE246246T1 (es)
AU (1) AU635744B2 (es)
CA (1) CA2050601C (es)
DE (2) DE69034091T2 (es)
DK (1) DK0402300T3 (es)
ES (2) ES2093640T3 (es)
FI (2) FI105104B (es)
GR (1) GR3021106T3 (es)
HU (1) HUT61591A (es)
IE (1) IE970086A1 (es)
IL (1) IL94361A (es)
NO (2) NO304027B1 (es)
NZ (1) NZ233642A (es)
SG (1) SG47987A1 (es)
WO (1) WO1990013645A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022849A (en) * 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
US6204009B1 (en) 1988-05-16 2001-03-20 BAXTER BIOTECH TECHNOLOGY SàRL Nucleic acids encoding mutant recombinant hemoglobins containing heme pocket mutations
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US6150506A (en) * 1989-05-10 2000-11-21 Baxter Biotech Technology Sarl Modified hemoglobin-like compounds and methods of purifying same
US5599907A (en) 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
US5844090A (en) * 1994-05-09 1998-12-01 Somatogen, Inc. Modified hemoglobin-like compounds
WO1991013158A1 (en) * 1990-02-28 1991-09-05 Delta Biotechnology Limited Protein production in yeast
CA2080589A1 (en) * 1990-04-16 1991-10-17 Joseph De Angelo Expression of recombinant hemoglobin in yeast
US6172039B1 (en) 1990-04-16 2001-01-09 Apex Bioscience, Inc. Expression of recombinant hemoglobin and hemoglobin variants in yeast
US5610137A (en) * 1990-12-20 1997-03-11 The Uab Research Foundation Transgenic, cross-linked hemoglobin
CA2098818A1 (en) * 1990-12-20 1992-06-21 Tim Townes Transgenic, cross-linked hemoglobin
US5714345A (en) * 1990-12-24 1998-02-03 Pharmaceutical Proteins Limited Increased expression of a gene by a second transferred mammary gland specific sequence transgenic
GB9028062D0 (en) * 1990-12-24 1991-02-13 Agricultural & Food Res Production of transgenic animals
WO1993008831A1 (en) * 1991-10-30 1993-05-13 Strohtech, Inc. Expression of recombinant hemoglobin and hemoglobin variants in yeast
US5679777A (en) * 1991-11-08 1997-10-21 Somatogen, Inc. Hemoglobins as drug delivery agents
FR2688784B1 (fr) * 1992-03-18 1995-06-30 Pasteur Merieux Serums Vacc Transporteur d'oxygene.
US5939391A (en) * 1993-03-31 1999-08-17 Pro-Neuron, Inc. Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation
US6610654B2 (en) 1993-03-31 2003-08-26 Wellstat Therapeutics Corporation Inhibitor of stem cell proliferation and uses thereof
DE69431473T2 (de) * 1993-03-31 2003-08-07 Pro-Neuron, Inc. Inhibitor der stammzellproliferation und seine verwendung
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5612310A (en) * 1993-05-24 1997-03-18 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5840851A (en) * 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
US5665869A (en) * 1993-11-15 1997-09-09 Somatogen, Inc. Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin
US6140071A (en) * 1994-01-27 2000-10-31 Somatogen, Inc. Proteins with mutations to decrease N-terminal methylation
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
WO1997004110A1 (en) * 1995-07-14 1997-02-06 Somatogen, Inc. Methods for increasing protein expression
US5824511A (en) * 1995-08-01 1998-10-20 University Technology Corporation Method for enhancing the production of hemoproteins
US6812207B1 (en) 1995-10-23 2004-11-02 William Marsh Rice University Hemoglobin mutants that reduce heme loss
WO1997015591A1 (en) * 1995-10-23 1997-05-01 Rice University Hemoglobin mutants that reduce heme loss
JP2000502058A (ja) * 1995-11-30 2000-02-22 ソマトジェン，インコーポレイテッド ヘモグロビン架橋の際の機能性制御のための方法
WO1997023631A2 (en) * 1995-12-22 1997-07-03 Somatogen, Inc. Globins containing binding domains
JP2000504934A (ja) 1995-12-22 2000-04-25 バクスター バイオテク テクノロジー エス．アー．アール．エル． 結合ドメインを含むグロビン
US5861483A (en) * 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
WO1998017809A1 (en) * 1996-10-18 1998-04-30 Baxter Biotech Technology S.A.R.L. Methods of reducing the levels of protoporphyrin ix in recombinant hemoglobin preparations
EP1950298A3 (en) 1997-05-02 2008-12-24 Baxter Biotech Technology S.A.R.L. Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
DE10036491A1 (de) * 2000-07-25 2002-02-07 Roche Diagnostics Gmbh Expression von Alkalischer Phosphatase in Hefe
DK1368483T3 (da) 2001-03-09 2012-11-05 Genentech Inc Fremgangsmåde til fremstilling af polypeptider
US7504377B2 (en) 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
WO2009014450A1 (en) * 2007-07-24 2009-01-29 Sanare As Novel peptides with anti-tumor activity
EP2058398A1 (en) * 2007-11-09 2009-05-13 Nipro Corporation Production of recombinant human hemoglobin using pichia yeast
US10752672B1 (en) * 2019-02-01 2020-08-25 Cheer Global Limited Recombinant hemoglobins and methods of preparation and use thereof
US20230073947A1 (en) * 2020-01-10 2023-03-09 Intron Biotechnology, Inc. A method for preparing bovine myoglobin using escherichia coli
EP4090678A4 (en) * 2020-01-10 2024-01-10 Intron Biotechnology, Inc. METHOD FOR PRODUCING PORK MYOGLOBIN USING ESCHERICHIA COLI
CN116203144B (zh) * 2022-05-11 2023-10-27 重庆医科大学附属儿童医院 测定血红蛋白中各型珠蛋白链比率的方法及其应用
KR20250113486A (ko) * 2022-11-30 2025-07-25 강마-헬스코드 (상하이) 바이오테크 컴퍼니 리미티드 재조합 헤모글로빈
WO2025246514A1 (zh) * 2024-05-30 2025-12-04 康码（上海）生物科技有限公司 一种无细胞合成血红素蛋白或肽链的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3924943A (en) 1974-06-11 1975-12-09 Xerox Corp Segmented biased transfer member
US4769326A (en) 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4599197A (en) 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GB8412517D0 (en) 1984-05-16 1984-06-20 Nagai K Recombinant fusion proteins
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4598064A (en) 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4774180A (en) 1986-02-26 1988-09-27 Massachusetts Institute Of Technology Construction and application of polyproteins
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
GB8701001D0 (en) 1987-01-19 1987-02-18 Gordon D G Ceiling tiles
WO1988006601A1 (en) 1987-03-02 1988-09-07 Genex Corporation Gene repressors
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
EP0561245A1 (en) * 1987-05-16 1993-09-22 Somatogenetics International, Inc. Blood substitutes comprising recombinant hemoglobin

Also Published As

Publication number Publication date
NO315568B1 (no) 2003-09-22
IL94361A (en) 1995-07-31
IE970086A1 (en) 2000-02-23
FI915279A0 (fi) 1991-11-08
EP0402300A2 (en) 1990-12-12
FI20000025L (fi) 2000-01-05
AU5675690A (en) 1990-11-29
EP0700997A1 (en) 1996-03-13
EP1380645A2 (en) 2004-01-14
EP0402300A3 (en) 1991-01-30
DE69034091T2 (de) 2004-04-22
HUT61591A (en) 1993-01-28
DE69028448D1 (de) 1996-10-17
NZ233642A (en) 1992-12-23
DE69028448T2 (de) 1997-02-06
EP0402300B1 (en) 1996-09-11
CA2050601C (en) 2000-09-19
ATE142692T1 (de) 1996-09-15
NO973848D0 (no) 1997-08-21
NO914387D0 (no) 1991-11-08
KR920701434A (ko) 1992-08-11
HU905111D0 (en) 1992-02-28
FI107938B (fi) 2001-10-31
CA2050601A1 (en) 1990-11-11
NO973848L (no) 1997-08-21
AU635744B2 (en) 1993-04-01
NO304027B1 (no) 1998-10-12
FI105104B (fi) 2000-06-15
NO914387L (no) 1991-11-08
ATE246246T1 (de) 2003-08-15
WO1990013645A1 (en) 1990-11-15
DK0402300T3 (da) 1996-09-30
ES2204926T3 (es) 2004-05-01
DE69034091D1 (de) 2003-09-04
JP3013902B2 (ja) 2000-02-28
JPH05503627A (ja) 1993-06-17
IL94361A0 (en) 1991-03-10
GR3021106T3 (en) 1996-12-31
SG47987A1 (en) 1998-04-17
EP0700997B1 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
EP0402300A3 (en) Production of bacteria and yeast of hemoglobin and analogues thereof
ES2827248T3 (es) Métodos de uso de Zscan4 para rejuvenecer células humanas
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
NL189092C (nl) Hybride menselijke leukocytinterferons, dubbelstrengs dna dat hiervoor codeert, expressievector, transformant micro-organisme, werkwijzen ter bereiding daarvan en farmaceutisch preparaat.
MX9707392A (es) Particulas a base de poliaminoacido(s) para utilizarse como vectores de principio(s) activo(s), y metodos para su preparacion.
DE69334257D1 (de) Methode zur Einführung von genetischem Material in Zellen
BR0009392A (pt) Polipeptìdeo, sequência de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, métodos para produzir uma sequência de ácido nucleico mutante e para produzir um polipeptìdeo, mutante de um polipeptìdeo com atividade de alafa-amilase, e, uso do polipeptìdeo ou variante
CN116218864A (zh) 一种重组Ⅲ型人源化胶原蛋白α1及其表达载体和应用
MX2023004125A (es) Celulas renales bioactivas inmunoprivilegiadas para el tratamiento de enfermedad renal.
WO2021011936A3 (en) Cell-type selective immunoprotection of cells
JP2021532094A5 (es)
AR120858A1 (es) VARIANTES DE a-GLUCOSIDASA ÁCIDA MANIPULADAS POR INGENIERÍA
ATE140009T1 (de) Interleukin-4 protein mit bcgf- und tcgf- aktivität gegenüber menschlichen zellen (menschliches interleukin-4)
JP2021532093A5 (es)
ES2052615T3 (es) Soluciones inyectables de gamma-globulina.
AR024771A1 (es) Genes y vacunas efectivas contra la calicivirosis felina, en particular vacunas recombinantes
ES551042A0 (es) Un procedimiento para producir glucagon o fragmentos o derivados del mismo en levadura
ES2006476A6 (es) Un procedimiento para obtener interleukin-2 humana
ES2058486T3 (es) Inmunogenos nativos y recombinantes del grupo b de eimeria tenella utiles como vacunas para las coccidiosis.
ES2076152T3 (es) Definicion y estructura de genes para proteasa a y proteasa b procedente de streptomices griseus.
ES2148526T3 (es) Formulaciones liquidas de ifn-beta.
RU2017123184A (ru) Лечение глазных патологий с применением клеток-предшественников
KR890006815A (ko) 산성 섬유아세포 생장인자의 돌연변이체
ES8304430A1 (es) "un procedimiento para obtener insulina humana".

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 402300

Country of ref document: ES